GHRP-6 is one of the original synthetic growth hormone releasing peptides — a hexapeptide that activates ghrelin receptors to stimulate GH release. Like GHRP-2, it produces off-target cortisol and prolactin elevation. Its defining characteristic is the intense appetite stimulation it causes through potent ghrelin receptor agonism — the most pronounced hunger effect in the GHRP class. This makes it uniquely useful for researchers studying appetite and GH simultaneously, or for individuals specifically seeking increased caloric intake alongside GH elevation.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
The primary practical difference is appetite stimulation. GHRP-6 causes intense hunger within 30–45 minutes of injection through potent ghrelin receptor agonism. GHRP-2 causes mild to moderate hunger.
How Does GHRP-6 Work?
GHRP-6 activates the ghrelin receptor (GHSR-1a) — the same mechanism as Ipamorelin and GHRP-2. The differences lie in potency and selectivity. GHRP-6 has strong activity at GHSR-1a but less receptor selectivity than Ipamorelin, producing cortisol and prolactin elevation similar to GHRP-2.
The intense hunger from GHRP-6 is mechanistically direct: ghrelin is one of the body's most potent appetite-stimulating hormones, and GHRP-6's strong GHSR-1a agonism produces a ghrelin-like appetite signal. Within 30–45 minutes of injection, many users experience intense food cravings. This effect typically diminishes with repeated use as ghrelin receptor sensitivity adapts.
GHRP-6 produces a meaningful GH pulse, comparable to GHRP-2 in magnitude. In the original literature from the 1990s, GHRP-6 was one of the first characterised synthetic GHRPs — it has a longer research history than both Ipamorelin and GHRP-2.
Historical Context and Research Base
GHRP-6 was synthesised and characterised by Cyril Bowers and colleagues in the late 1970s and 1980s — it predates most of the modern GHRP class and was the foundational compound from which Ipamorelin and GHRP-2 were developed. The early characterisation work established the ghrelin receptor pathway as a distinct GH-stimulating mechanism.
The original research validated GHRP-6 as a potent, reliable GH secretagogue in both animals and humans. Subsequent development focused on improving selectivity — reducing the cortisol, prolactin, and hunger effects — which led to GHRP-2 (improved selectivity over GHRP-6) and eventually Ipamorelin (maximum selectivity, essentially no cortisol or prolactin).
Community use has retained GHRP-6 primarily for contexts where the appetite stimulation is desired: hardgainers trying to increase caloric intake, post-illness recovery where appetite restoration is the goal, or protocols where the hunger effect is considered acceptable for the GH benefits.
What Is the Recommended GHRP-6 Dosage?
| Protocol | Dose | Route | Timing | Notes |
|---|---|---|---|---|
| Standard | 100–200 mcg | SubQ | Fasted, 2–3x daily | Have food ready for hunger |
| Appetite stimulation | 200–300 mcg | SubQ | 30 min before meals | Use hunger for caloric intake |
| Combined with CJC-1295 | 100 mcg GHRP-6 + 100 mcg CJC | SubQ | Fasted | Synergistic GH release |
The Hunger Effect and Other Side Effects
**Intense hunger:** GHRP-6's defining feature. Within 30–45 minutes of injection, appetite increases dramatically. For hardgainers this is an advantage. For anyone managing caloric intake or weight, it's a significant drawback. The hunger effect typically reduces over 1–2 weeks of use as receptor adaptation occurs.
**Cortisol and prolactin elevation:** Similar to GHRP-2. Both increase meaningfully with GHRP-6 injection. Less selective than Ipamorelin for GH-specific effects.
**Water retention:** Standard GH secretagogue effect, dose-dependent.
**Timing food intake around GHRP-6:** Most protocols inject GHRP-6 about 30 minutes before a meal to align the hunger peak with planned eating. This converts the side effect into a benefit for meal compliance and caloric intake.
**GHRP class comparison summary:** GHRP-6 is most useful when appetite stimulation is a goal. For clean GH optimisation without hunger or cortisol effects, Ipamorelin is the superior choice. GHRP-6 and GHRP-2 have largely been supplanted by Ipamorelin in modern protocols except for specific use cases.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
The primary practical difference is appetite stimulation. GHRP-6 causes intense hunger within 30–45 minutes of injection through potent ghrelin receptor agonism. GHRP-2 causes mild to moderate hunger. Both produce cortisol and prolactin elevation. GH pulse amplitude is comparable between the two. GHRP-6 is preferred when appetite stimulation is desired; GHRP-2 when minimising hunger is the priority.
GHRP-6 elevates GH, which downstream elevates IGF-1 — both anabolic signals. In combination with a GHRH analog (CJC-1295), the combined GH pulse is synergistically larger. The intense hunger effect of GHRP-6 also facilitates caloric surplus maintenance for muscle building. For pure anabolic outcomes without hunger, Ipamorelin + CJC-1295 is more common in modern protocols.
For most applications, Ipamorelin is preferred — cleaner side effect profile, no cortisol or prolactin elevation, comparable GH pulse without hunger. GHRP-6 is specifically useful when appetite stimulation is a goal. The 'better' answer depends on what you need: if hunger is welcome, GHRP-6 has advantages. If not, Ipamorelin is superior.
Yes — this is a classic combination. CJC-1295 (GHRH analog) and GHRP-6 (GHRP) work on separate receptor pathways synergistically. The combined GH pulse is substantially larger than either alone. Use the same fasted timing and inject both simultaneously. Account for the hunger that follows GHRP-6 by having food prepared.
Both stimulate GH through the ghrelin receptor and both cause significant appetite stimulation. MK-677 is orally active (no injection) with a 24-hour half-life. GHRP-6 is injectable with a short half-life requiring multiple daily doses. MK-677 is generally more convenient; GHRP-6 allows more precise pulse timing. Both elevate cortisol and cause water retention.
Primary side effects: intense hunger (within 30–45 min of injection), cortisol elevation, prolactin elevation, and water retention. The hunger is the most notable and often the most practically significant. These distinguish GHRP-6 from Ipamorelin, which produces minimal off-target hormonal effects.